Vident Advisory’s ResMed RMD Stock Holding History

Vident Advisory’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.37M	Sell	7,008 -2,086	-23%	-$432K	0.01%	828
2026 Q1	$2.04M	Buy	9,094 +540	+6%	+$135K	0.02%	619
2025 Q4	$2.06M	Sell	8,554 -1,056	-11%	-$270K	0.02%	574
2025 Q3	$2.63M	Sell	9,610 -11,931	-55%	-$3.26M	0.03%	481
2025 Q2	$5.56M	Buy	21,541 +1,260	+6%	+$301K	0.06%	252
2025 Q1	$4.54M	Buy	20,281 +3,153	+18%	+$736K	0.07%	259
2024 Q4	$3.92M	Buy	17,128 +982	+6%	+$236K	0.07%	258
2024 Q3	$3.94M	Buy	16,146 +12,339	+324%	+$2.76M	0.1%	204
2024 Q2	$729K	Sell	3,807 -2,805	-42%	-$569K	0.02%	713
2024 Q1	$1.31M	Buy	6,612 +1,251	+23%	+$229K	0.03%	499
2023 Q4	$922K	Buy	5,361 +3,535	+194%	+$543K	0.02%	582
2023 Q3	$270K	Buy	+1,826	New	+$330K	0.01%	971

Other funds holding RMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vident Advisory's RMD Position: Q2 2026 in Review

Vident Advisory reduced its ResMed (RMD) stake by 23% in Q2 2026, selling an estimated $432K and leaving 7,008 shares worth $1.37M. The position accounts for 0.01% of the portfolio, ranked #828.

Vident Advisory first reported a position in RMD in Q3 2023 and has held it in 12 quarters since. The position peaked at $5.56M in Q2 2025. 882 funds tracked by Wall St. Rank hold RMD as of Q2 2026.

Vident Advisory held 7,008 shares of ResMed worth $1.37M as of Q2 2026.
Vident Advisory sold 2,086 ResMed shares in Q2 2026, an estimated $432K.
ResMed made up 0.01% of Vident Advisory's portfolio in Q2 2026, its #828 holding.
Vident Advisory first reported a position in ResMed in Q3 2023 and has held it in 12 quarters since.
Vident Advisory's ResMed position peaked at $5.56M in Q2 2025.
882 funds tracked by Wall St. Rank held ResMed as of Q2 2026.

Based on Vident Advisory's 13F filing for Q2 2026, filed 12 Aug 2026.